Contact this trialFirst, we need to learn more about you.
Immune Checkpoint Inhibitor
Durvalumab + Olaparib for Endometrial Cancer
Recruiting1 awardPhase 3
Chattanooga, Tennessee
This trial is testing a new combination treatment for endometrial cancer that could potentially improve outcomes and side effects.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.